Key result
Complete revascularisation of non-culprit lesions is recommended for all acute coronary syndrome patients with multivessel disease, except those presenting with cardiogenic shock.
Why the study?
Despite numerous clinical trials, several questions regarding complete coronary revascularisation in ACS patients with multivessel disease remain unanswered.
Does complete coronary revascularisation improve outcomes in patients presenting with acute coronary syndromes and multivessel disease?
Does complete coronary revascularisation improve outcomes in patients presenting with acute coronary syndromes and multivessel disease?
This review summarizes the latest evidence on complete revascularization in ACS patients with multivessel disease and appraises clinical decision making based on non-culprit lesion assessment.
Further trials needed to resolve CR uncertainties in ACS-MVD; leaves open optimal NCL assessment strategies.
A significant proportion of patients presenting with acute coronary syndromes (ACS) have multivessel disease (MVD). Despite the abundance of clinical trials in this area, several questions regarding the procedure of complete coronary revascularisation remain unanswered. This state-of-the-art review summarises the latest evidence on complete revascularisation (CR) in this subset of patients and critically appraises clinical decision making based on non-culprit lesion (NCL) assessment. Future areas of research are put into perspective.
No takes yet. Share an insight, caveat, or question.
Paradies et al. (2021) conducted a review in Acute coronary syndrome with multivessel disease. Complete revascularisation vs. Culprit-only revascularisation was evaluated. Complete revascularisation of non-culprit lesions is recommended for all acute coronary syndrome patients with multivessel disease, except those presenting with cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: